Previous 10 | Next 10 |
United Therapeutics Corporation To Report Third Quarter 2021 Financial Results Before The Market Opens On Wednesday, November 3, 2021 PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 27, 2021 /PRNewswire/ -- United Therapeutics Corp...
United Therapeutics Details New Data Presented at CHEST Annual Meeting 2021 Tyvaso DPI™ BREEZE pharmacokinetic data demonstrate similar exposure and lower variability for Tyvaso DPI compared with Tyvaso® Ten abstracts covering Tyvaso (treprostinil) Inhalation Sol...
Shares of MannKind (NASDAQ: MNKD) , a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (NASDAQ...
United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application Draft label contains both PAH and PH-ILD indications; no contraindications and no boxed warning Complete response cites an open inspection issue at a third-party analytical ...
United Therapeutics to Present New Data at CHEST Annual Meeting 2021 A total of 10 abstracts reinforce United Therapeutics' commitment to advancing research in pulmonary hypertension Additional subgroup analyses evaluate data from the Tyvaso® INCREASE study in PH-ILD ...
MannKind (MNKD +3.8%) shares are up in advance of an upcoming FDA decision on its NDA for Tyvaso DPI (inhaled treprostinil) for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The FDA granted priority review to the ca...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Given all the talk about the pandemic, the delta variant and everything else, it would be easy to believe that pharmaceutical stocks are doing well this year. But the fact is, according to the benchmark S&P Pharmaceutic...
United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval Conversion officially aligns corporate charter with longstanding commitment to improve the lives of patients while creating sustainable shareholder value in a responsible manner PR Ne...
I will share the history of inhalable medical drugs. Readers will be able to see who has been highly successful in creating and marketing inhalable drugs. I will update my long-term held opinion on Afrezza becoming a viable drug for diabetics. For further details see: Ma...
HHS has sent letters to six pharmaceutical companies saying they may now face fines for refusing to appropriately comply with the federal government's 340B drug discount program. The companies are: AstraZeneca (AZN +1.1%), Eli Lilly (LLY +2.0%), Novartis (NVS +1.2%), Novo Nordisk (NVO +1...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...